TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06739733

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SRG
Description: Soft robotic gloves stimulation 30-minute sessions, 5 times per week upto 8 week Soft robotic gloves are assistive devices designed to enhance hand function for individuals with disabilities or injuries. These gloves use flexible materials, such as silicone or fabric, combined with pneumatic or cable-driven mechanisms to mimic natural hand movements. They provide assistance for gripping, holding, or manipulating objects, often controlled by sensors or user inputs. Soft robotic gloves are lightweight, adaptable, and offer rehabilitation potential, helping restore motor function in conditions like stroke or spinal cord injury. They are increasingly used in clinical and home-based therapy settings.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: EMS
Description: Electrical muscle stimulation 30-minute sessions, 5 times per week upto 8 weeks.~Electrical Muscle Stimulation (EMS) is a technique that uses electrical impulses to contract muscles, often used for rehabilitation, strength training, or pain management. Electrodes placed on the skin deliver controlled currents to target specific muscle groups, mimicking natural nerve signals. EMS is commonly used in physiotherapy to prevent muscle atrophy, improve circulation, and enhance recovery after injury. It is also utilized in fitness and sports for performance enhancement. Safe and non-invasive, EMS can be adjusted for therapeutic or functional goals.
Study: NCT05880589

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk secretory supplement group
Description: Take 2 tablet 2 times per day for 14 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Take 2 tablet 2 times per day for 14 days
Study: NCT06609889

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ION283
Description: Anti-sense Oligonucleotide therapy that includes intrathecal (IT) injections by lumbar puncture (LP) with dose level of 15 mg.
Study: NCT04992390

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief digital imagery-competing task intervention
Description: First session guided by a researcher: A memory cue followed by playing the brief digital imagery-competing task with mental rotation instructions.~Option to engage in self-administered/guided sessions after the first session and record their intrusive memories (symptom monitoring).
Study: NCT06023576

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Symptom-limited cardiopulmonary exercise test
Description: Consecutive patients in each treatment group who meet the eligibility criteria for exercise testing will be offered to participate in CPET at the time of consent. Patients who agree will undergo CPET (baseline, 6 months, and 12 months) until the target accrual of 33 patients per group is met.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of Life Measures
Description: FACT-B, Fatigue Symptom Inventory (FSI), Patient Reported Outcomes Measurement Information System (PROMIS) Global Health Scale, Godin Leisure Time Exercise Questionnaire (GLTEQ),PROMIS Medication Adherence Scale. Given baseline, 3 months and 12 months.
Study: NCT06023576

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of Life Measures
Description: FACT-B, Fatigue Symptom Inventory (FSI), Patient Reported Outcomes Measurement Information System (PROMIS) Global Health Scale, Godin Leisure Time Exercise Questionnaire (GLTEQ),PROMIS Medication Adherence Scale. Given baseline, 3 months and 12 months.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Biomarkers
Description: Research blood samples will be collected at baseline, 3 months, and 6 months

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Biomarkers
Description: Research blood samples will be collected at baseline, 3 months, and 6 months
Study: NCT06329843

Intervention type: DEVICE
Intervention: Picterus Jaundice Pro (JP)
Description: Picterus Jaundice Pro photos will be obtained of enrolled subjects each time the patient has a serum bilirubin level obtained. Up to five paired measurements will be obtained per enrolled subject. The study nurse will place the proprietary calibration card over the subject's sternum and take six Picterus Jaundice Pro photos using a study iPhone within one hour of the serum bilirubin draw. This process takes less than one minute. After the study photos are obtained, the study nurse will record the serum and Picterus Jaundice Pro values in the data-recording log.~In the event an enrolled infant requires phototherapy, a light occlusive adhesive patch will be placed over the center of the chest before phototherapy initiation. When a serum bilirubin level is obtained, the research nurse will remove the patch for a brief moment to take Picterus Jaundice Pro pictures (within one hour of the serum value draw).
Study: NCT04511039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine and Tipiracil Hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib Tosylate
Description: Given PO
Study: NCT05546788

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Received placebo gel
Study: NCT05194917

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Older Smoker Motivational Intervention
Description: OSMI identified in Aim 2 of the study, motivational interventions will be delivered via mailer with QR video code.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Motivational Message
Description: One control motivational message with a standard health- and EBST access-related content (i.e., Quitting smoking is the best thing you can do for your health. Call 1-800-QUIT-NOW for help.), motivational interventions will be delivered via mailer with QR video code.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Motivational Message
Description: One control motivational message with a standard health- and EBST access-related content (i.e., Quitting smoking is the best thing you can do for your health. Call 1-800-QUIT-NOW for help.), motivational interventions will be delivered via mailer with QR video code.
Study: NCT06207344

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine and propofol
Description: Group 1: After anesthesia induction, dexmedetomidine was infused at 1 μg/kg intravenously within 15 min, then infused at 0.3 μg/kg/h until 30 min before the end of the operation. Meantime, propofol was infused at 4-12mg/kg/h intravenously to maintain the depth of anesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine and desflurane
Description: Group 2: After anesthesia induction, dexmedetomidine was infused at 1 μg/kg intravenously within 15 min, then infused at 0.3 μg/kg/h until 30 min before the end of the operation. At the same time, 2.5%-8.5% desflurane was inhaled to maintain the depth of anesthesia.
Study: NCT04310137

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapist-Directed Re-loading
Description: Therapist will specifically direct participant to increase walking by 10% as measured at each of the activity monitoring assessments. In addition, the participant will be asked to monitor foot temperature to mitigate risk for breakdown.
Study: NCT05324033

Intervention type: RADIATION
Intervention: multiparametric MRI on the bladder
Description: comparison between mpMRI and histopathology

Intervention type: RADIATION
Intervention: multiparametric MRI on the bladder
Description: comparison between mpMRI and histopathology

Intervention type: PROCEDURE
Intervention: diagnostic cystoscopy +/- TURBT
Description: conventional way of diagnosis

Intervention type: PROCEDURE
Intervention: diagnostic cystoscopy +/- TURBT
Description: conventional way of diagnosis
Study: NCT06316323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride
Description: 38% Silver Diamine Fluoride (SDF) is a topical antimicrobial and remineralizing agent which was cleared by the FDA as a Class II medical device to treat tooth sensitivity. In certain circumstances, SDF may be used as a non-restorative treatment to arrest carious lesions on primary and permanent teeth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium fluoride
Description: Fluoride varnish to apply on tooth surface, so that the tooth becomes more resistant to caries attack. The active ingredient of fluoride varnish is 5% sodium fluoride, (22,600 ppm fluoride)
Study: NCT05092516

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: 2 mA of anodal stimulation will be applied to the left prefrontal cortex over the F3 electrode based on the International 10-10 EEG system.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Sham stimulation will be applied to the left prefrontal cortex over the F3 electrode.
Study: NCT05431127

Intervention type: DEVICE
Group type: OTHER
Intervention: IMT therapy using the Pr02 mobile device
Description: Inspiratory Muscle Training using a device used to measure and increase respiratory strength and performance through resisted breathing exercises.
Study: NCT05907499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine 6 mg/m2 daily subcutaneously for consecutive 3 days (day 1 to day 3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor
Description: 5ug/kg/d when absolute neutrophil count ≤ 1.5 × 109/L

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granulocyte Colony-Stimulating Factor
Description: 5ug/kg/d when absolute neutrophil count ≤ 1.5 × 109/L

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thrombopoietin Receptor Agonist
Description: Eltrombopag initial dose: 25 mg orally once a day, may increase to up to 75 mg/day, when platelet count ≤ 30 × 109/L; Avatrombopag initial dose: 20 mg orally once a day, may increase to up to 60 mg/day, when platelet count ≤ 30 × 109/L.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thrombopoietin Receptor Agonist
Description: Eltrombopag initial dose: 25 mg orally once a day, may increase to up to 75 mg/day, when platelet count ≤ 30 × 109/L; Avatrombopag initial dose: 20 mg orally once a day, may increase to up to 60 mg/day, when platelet count ≤ 30 × 109/L.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin
Description: 10000 U/day when hemoglobin ≤ 85 g/L

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human erythropoietin
Description: 10000 U/day when hemoglobin ≤ 85 g/L
Study: NCT05976984

Intervention type: OTHER
Intervention: Aim 1 (case-cohort study)
Description: * Cases: All Medicaid enrollees age 15 years or older with at least one inpatient hospitalization or emergency department visit indicating a stimulant overdose during 2016-2020~* Subcohort: A random sample of all Medicaid enrollees age 15 years or older irrespective of their stimulant overdose history during 2016-2020

Intervention type: OTHER
Intervention: Aim 2 (case-crossover study)
Description: * Case period: 60 days before the date of stimulant overdose through the day before the date of stimulant overdose~* Control period: 179 days before the date of stimulant overdose through 120 days before the date of stimulant overdose~* Washout period: 119 days before the date of stimulant overdose through 61 days before the date of stimulant overdose

Intervention type: OTHER
Intervention: Aim 3 (cohort study)
Description: All Medicaid enrollees age 15 years or older with at least one inpatient hospitalization or emergency department visit indicating a stimulant overdose during 2016-2020
Study: NCT04792970

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Talc
Description: All patients randomized to the Talc arm will receive Talc therapy through the pleural catheter.
Study: NCT04880590

Intervention type: OTHER
Intervention: Sex intercourse
Description: A heterosexual sexual relationship
Study: NCT05821647

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HPI guided treatment advice
Description: Administer hemodynamic altering intervention aimed at either a preload, contractility, or afterload problem to prevent impending hypotension. Treatment options include: administering either fluids, inotropes, vasopressors, positional changes, or a combination.
Study: NCT04505163

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Cryoballoon Pulmonary Vein Isolation (PVI)
Description: Arctic Front Advance cryoballoon ablation system to ablate the pulmonary veins to achieve PVI alone

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoballoon PVI + Posterior Wall Isolation
Description: Arctic Front Advance Cardiac Cryoballoon Ablation System to ablate the pulmonary veins and the left atrial posterior wall to achieve PVI + posterior wall isolation within the region of the pulmonary venous component
Study: NCT05713955

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Obsidian
Description: To create OBSiDiAN BioMatrix, 120 ml of the the patient's blood is added to the processing unit. The Vivostat® processor unit heats, separates, centrifugates to get the plasma. Batroxobin is added. After again processing, the result is an OBSiDian syringe filled with BioMatrix Obsidian®ASG. This will be applied on the anastomosis
Study: NCT06081465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VG290131
Description: The study drug and matching placebo will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VG290131
Description: The study drug and matching placebo will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VG290131
Description: The study drug and matching placebo will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VG290131
Description: The study drug and matching placebo will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VG290131
Description: The study drug and matching placebo will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VG290131
Description: The study drug and matching placebo will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VG290131
Description: The study drug and matching placebo will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VG290131
Description: The study drug and matching placebo will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VG290131
Description: The study drug and matching placebo will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VG290131
Description: The study drug and matching placebo will be administered orally.
Study: NCT06512090

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LGI steam bread
Description: LGI Steam bread called Mangusteam bread

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Diabetic diet
Description: the calorie intake of Diabetic diet will by recommended by nutritionist
Study: NCT05610150

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Myobrace Functional Appliance
Description: An Appliance for treating growing Class II patients with mandibular deficiency

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Twin Block
Description: An Appliance for treating growing Class II patients with mandibular deficiency
Study: NCT06511427

Intervention type: DIAGNOSTIC_TEST
Intervention: upper airway sonography
Description: clinical evaluation of upper airway, ultrasonographic assessement

Intervention type: DIAGNOSTIC_TEST
Intervention: upper airway sonography
Description: clinical evaluation of upper airway, ultrasonographic assessement
Study: NCT06125379

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: brief mindfulness
Description: The mindfulness intervention protocol in this study is an adaptation of the Mindfulness Based Stress Reduction (MBSR) protocol with the cultural adaptation suits Indonesia population with addition of Islamic elements (i.e., a series of spiritual approaches) to improve emotional regulation, make sense of their life, be grateful and feel closer to God.
Study: NCT04685291

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided block of the supraclavicular nerves
Description: The supraclavicular nerves (SCN) arise from the 3rd and 4th roots of the spinal nerves. After emerging from the spine, they run at the rear margin of the sternocleidomastoid muscle and divide into their three terminal branches. With a high-resolution Ultrasound (US)-probe they can be visualized as a grape-like structure under the skin. At this location, patient's skin is disinfected and covered with a sterile perforated blanket. The US-probe is covered with a sterile sheath. The patient is positioned as comfortably as possible so that the broken clavicle is not mobilized. SCN are shown by US and a 0.5 mm needle is advanced through the patient's skin in order to direct it to the nerves under US-guidance. Both the nerves and the needle are permanently visualized. As soon as the needle tip is placed next to the SCN, 2-3 millilitres of a long-acting LA are injected. The distribution of the LA around the nerves is controlled.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional pain management
Description: * oral pain medication in patients younger than 70 years: Ibuprofen 400mg (1-1-1) AND Metamizole 500mg (max. 2 tbl. every 6 hours)~* oral pain medication in patients older than or equal 70 years: Acemetacin 60mg (1-1-1) AND Metamizole 500mg (max. 2 tbl. every 6 hours)~* Rescue analgesic medication for all patients: oxycodone hydrochlorid (drops) p.o. (10 mg/ml) 0.1mg/kg p.o. hour~* In the ED Rescue analgesic medication for all patients: Fentanyl 50mcg i.v. (max. 200mcg/hour)
Study: NCT06140238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parecoxib
Description: Parecoxib administration 15 minutes before start surgical operation
Study: NCT04584307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Description: Elotuzumab 10-20mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide 2mg
Study: NCT06140238

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline administration 15 minutes before start surgical operation
Study: NCT06410638

Intervention type: DIAGNOSTIC_TEST
Intervention: Six Minute Walking Test
Description: It is applied in a 30 m long corridor in an indoor environment, and the distance walked by the patient in a six-minute period, oxygen saturation, heart rate, and change in dyspnea are recorded. For this, before starting the test, oxygen saturation, heart rate, arterial blood pressure and dyspnea level according to the Borg scale are recorded. The same parameters are measured again at the end of the test. The feature of this test is that the person walks at his own pace, stopping when necessary and allowing the use of oxygen. It is an exercise test that is easy to perform and well tolerated.

Intervention type: DIAGNOSTIC_TEST
Intervention: Shuttle walking test
Description: Shuttle walking test at increasing speed is an exercise test in which walk between two cones 10 m apart at an increasing speed throughout the test and each 10-meter journey between the two cones is counted as a shuttle.
Study: NCT06329115

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Within the physical activity program, an aerobic training program will be applied to students for a total of 150 minutes per week for 8 weeks. Aerobic training includes moderate-intensity walking exercise. The concept of moderate walking will be explained to individuals at the beginning of the study. Maximal and submaximal heart rate calculations will be made with the formulas (220-age) / (220-age X 0.6) and this heart rate will be maintained throughout the training. Students will have a pedometer application installed on their phones and their step counts and exercise minute data will be recorded. At the same time, in order for students to use their respiratory functions properly during regular walking, diaphragmatic breathing and alternating nose breathing breathing exercises will be taught and they will be instructed to do them once a day with 5 repetitions.
Study: NCT05043285

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTV01C
Description: intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTV01C
Description: intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTV01C
Description: intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTV01C
Description: intramuscular injection
Study: NCT05284513

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Implementation strategy package: Stage implementation scale up
Description: Develop the timeline for the stepped-wedge rollout to primary care

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Implementation strategy package: Stage implementation scale up
Description: Develop the timeline for the stepped-wedge rollout to primary care
Study: NCT05043285

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injection
Study: NCT05526209

Intervention type: PROCEDURE
Intervention: using longitudinal relaxing incision as a technique for recurrence prevention in ventral hernia
Description: using longitudinal relaxing incision as a technique for recurrence prevention in ventral hernia
Study: NCT05284513

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Implementation strategy package: Stage implementation scale up
Description: Develop the timeline for the stepped-wedge rollout to primary care

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Implementation strategy package: Stage implementation scale up
Description: Develop the timeline for the stepped-wedge rollout to primary care

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Implementation strategy package: Stage implementation scale up
Description: Develop the timeline for the stepped-wedge rollout to primary care
Study: NCT05108974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Choline Bitartrate
Description: Powdered drink mix for daily consumption

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Choline Bitartrate
Description: Powdered drink mix for daily consumption
Study: NCT05645692

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: Participants will receive 1200 mg IV atezolizumab Q3W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobemstomig
Description: Participants will receive 600 mg IV tobemstomig Q3W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobemstomig
Description: Participants will receive 600 mg IV tobemstomig Q3W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Participants will receive 600 mg IV tiragolumab Q3W.